Efficiency of firmagon in patients with advanced prostate cancer after progression after standard treatment with MAB scheme: clinical case report
https://doi.org/10.18027/2224-5057-2014-1-47-51
Abstract
Prostate cancer is the most common form of cancer in men in Western countries and in some countries is in second place in the list of leading causes of cancer death in men. About 300 000 new cases of prostate cancer registered in Europe annually. This number increases to 670,000 cases worldwide.
About the Authors
M. V. Kazantseva
ГБУЗ «Клинический онкологический диспансер №1», департамента здравоохранения Краснодарского края
Russian Federation
Russian Federation
E. A. Strygina
ГБУЗ «Клинический онкологический диспансер №1», департамента здравоохранения Краснодарского края
Russian Federation
Russian Federation
References
1. Казанцева М. В., Тесленко Л. Г., Цокур И. В., Бондарева И. С. Распространённость злокачественных новообразований в Краснодарском крае (200–20 годы). — Краснодар, 2011. — С. 151.
2. ФГБУ Российский научный центр рентгенорадиологии Минздравсоцразвития РФ (Москва). Павлов А. Ю., Гафанов Р. А., Фастовец С. В., Герасимов А. А., Исаев Т. К. Опыт применения Фирмагона в комбинации с сочетанной лучевой терапией у больных раком предстательной железы.
3. Tombal B. et al. Lower risk of cardiovascular (C V) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists. EAU 2013, Poster #677.
4. Miller K. et al. Lower risk of cardiovascular (C V) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists. EAU 2013, Poster #678.
5. Klotz L. et al. BJU Int 2008; 102:1531–1538.
6. Firmagon (degarelix). Summary of product characteristics. July 2012.
7. Tombal B et al. Eur Urol 2010; 57:836–42.
8. Crawford ED et al. J Urol 2011;186 (3): 889–897.
9. Van Poppel H et al. Abstract (23.) Euro Urol Suppl 2007; 6 (2):28.
Review
For citations:
Kazantseva M.V., Strygina E.A. Efficiency of firmagon in patients with advanced prostate cancer after progression after standard treatment with MAB scheme: clinical case report. Malignant tumours. 2014;(1):47-51. (In Russ.) https://doi.org/10.18027/2224-5057-2014-1-47-51
Views:
893
Email this article 